Timing of Testosterone Level Draw for Weekly Injections
For patients receiving weekly testosterone enanthate or cypionate injections, draw the testosterone level midway between injections (approximately 3-4 days after injection) when monitoring therapy. 1
Rationale and Clinical Context
The Endocrine Society Clinical Practice Guideline explicitly states that for injectable testosterone enanthate or cypionate, serum testosterone should be measured midway between injections 1. This timing captures a representative level that reflects the patient's average testosterone exposure during the dosing interval, avoiding both the early peak (which occurs 2-5 days post-injection) and the late trough (which occurs just before the next dose).
Initial Monitoring Timeline
- First testosterone level check: 3-6 months after initiating therapy 1
- Target range: Mid-normal testosterone range (approximately 450-600 ng/dL) 1, 2
- Dose adjustment criteria: If testosterone is >700 ng/dL or <400 ng/dL at midpoint, adjust dose or frequency 1
Why Midpoint Timing Matters
With weekly injections of short-acting testosterone esters, serum levels fluctuate significantly across the dosing cycle 3. Peak levels occur 2-5 days after injection, with return toward baseline by 10-14 days 4. For weekly dosing:
- Too early (1-2 days post-injection): Captures artificially elevated peak levels
- Midpoint (3-4 days post-injection): Represents average therapeutic exposure
- Too late (6-7 days post-injection): May show declining levels that don't reflect overall adequacy
Practical Implementation
For a patient injecting every Monday:
- Schedule blood draw on Thursday or Friday morning (3-4 days post-injection)
- Draw should still be performed in the morning (before 11 AM) when possible, though the circadian variation is less pronounced in men on exogenous testosterone 5, 6, 7
Additional Monitoring Parameters
Beyond testosterone level timing, comprehensive monitoring includes:
- Hematocrit: Baseline, 3-6 months, then annually (stop therapy if >54%) 1
- PSA and digital rectal exam: For men ≥40 years with baseline PSA >0.6 ng/mL, check at 3-6 months then per screening guidelines 1
- Clinical response assessment: Evaluate symptoms at 3-6 months and annually 1
Common Pitfalls to Avoid
- Drawing at trough (just before next injection): This approach is appropriate for long-acting testosterone undecanoate 1 but will underestimate exposure with weekly short-acting esters
- Random timing without documentation: Always document when the last injection was given relative to the blood draw 3
- Single abnormal result: If levels are borderline, repeat testing to account for variability 7
- Ignoring free testosterone: When total testosterone is borderline (400-700 ng/dL), calculate free testosterone using total testosterone, SHBG, and albumin 1, 5
Alternative Dosing Considerations
If midpoint levels are therapeutic but the patient reports symptom cycling (early peak-related effects like acne, mood changes, or late-cycle fatigue and reduced libido), consider more frequent injections at lower doses (e.g., twice weekly) rather than increasing the total weekly dose 3. This creates more stable serum levels without increasing total testosterone exposure.